Carisma Therapeutics Announces Clinical & Preclinical Updates at 37th Annual SITC Meeting
Current TAP Partner
PHILADELPHIA – November 11, 2022 – Carisma Therapeutics Inc. (Carisma Therapeutics), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting additional findings from its CT-0508 chimeric antigen receptor macrophage (CAR-M) clinical trial for patients with advanced metastatic human epidermal growth factor receptor 2 (HER2) overexpressing solid tumors, supporting a favorable safety profile and manufacturing feasibility of its proprietary engineered cell therapy platform.
Details of Carisma Therapeutics’ data also accepted for presentation at the SITC 37th Annual Meeting:
- “Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508,” Friday, November 11 at 12:18pm EST
- “Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy,” Thursday, November 10
- “A Phase 1, First in Human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors,” Thursday, November 10
- “Pre-clinical development of a CAR Monocyte platform for cancer immunotherapy,” Friday, November 11